Provided by Tiger Trade Technology Pte. Ltd.

Franklin Genomic Advancements ETF

42.47
+0.51461.23%
Post-market: 42.470.00000.00%16:10 EDT
Volume:168
Turnover:7K
Market Cap:31.85M
PE:- -
High:42.47
Open:41.95
Low:42.47
Close:41.95
52wk High:43.51
52wk Low:29.80
Shares:750.00K
Float Shares:750.00K
Volume Ratio:0.21
T/O Rate:0.02%
Dividend:0.14
Dividend Rate:0.33%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Precision Biology Reshapes Nutrition: Expert Discusses Tech-Driven Solutions for Every Life Stage

Deep News
·
Yesterday

Guardant Health Price Target Maintained with a $195.00/Share by BTIG

Dow Jones
·
Yesterday

Analysts Are Bullish on Top Healthcare Stocks: Medtronic (MDT), Guardant Health (GH)

TIPRANKS
·
Yesterday

Guardant Health Shield Blood Test Wins Carelon Coverage for Colorectal Cancer Screening

Reuters
·
Sep 01

Natera announces publication of new data in Blood Neoplasia on Signatera

TIPRANKS
·
Sep 01

CytoDyn Net Loss Widens to $42.7 Million in FY26

Reuters
·
Aug 31

Is Ligand Pharmaceuticals (LGND) Undervalued On Its Conference Appearance?

Simply Wall St.
·
Aug 30

Does Guardant Health’s (GH) Patent Appeal Reshape Its Competitive Moat More Than Its Royalty Bill?

Simply Wall St.
·
Aug 30

Adaptive Biotechnologies Director Katey Einterz Owen Sells 9,615 Shares for $249,990

Reuters
·
Aug 29

Natera and Susan G. Komen® Announce National Partnership to Accelerate Progress Against Breast Cancer

THOMSON REUTERS
·
Aug 28

Adaptive Biotechnologies (ADPT), Why Is It Getting Fresh Attention Now?

Simply Wall St.
·
Aug 28

ABL Diagnostics Calls Shareholder Vote on Move to Euronext Growth and Name Change

TIPRANKS
·
Aug 28

Natera and Angiex partner in tumor testing using Signatera

TIPRANKS
·
Aug 27

Natera Partners with Angiex to Use Signatera ctDNA Test in Agx101 Phase I Trial Monitoring

Reuters
·
Aug 27

Natera, - Announces Signatera Collaboration with Angiox to Assess Nd-ADC Therapy Response

THOMSON REUTERS
·
Aug 27

Natera, - Collaboration Includes Longitudinal Signatera Ctdna Testing for Agx101 Response Monitoring

THOMSON REUTERS
·
Aug 27

Fujian Unveils Plans to Boost Cross-Strait Biotech and Medical Collaboration Zone

Deep News
·
Aug 27

Ligand Targets $150-$250 Million in Annual Investments as Royalty Revenue Tops $225 Million in 2026 Guidance

Reuters
·
Aug 26

Ligand Management Participates in Wells Fargo Healthcare Conference Fireside Chat

Reuters
·
Aug 26

Unified Pathology Index Launches Nationwide, One Code Bridges Data Gaps for Precision Care

Stock News
·
Aug 26